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AKR1C3 is a novel therapeutic target in castration-resistant prostate cancer (CRPC) and  
estrogen receptor (ER)-positive breast cancer because of its ability to produce testosterone  
and 17β-estradiol intratumorally, thus promoting nuclear receptor signaling and tumor pro-  
gression. A panel of CRPC, ER-positive breast cancer and high/low AKR1C3-expressing cell  
lines were treated with SN33638, a selective inhibitor of AKR1C3, in the presence of hor-  
mone or prostaglandin (PG) precursors, prior to evaluation of cell proliferation and levels of  
11β-PG F2α (11β-PGF ),  2α testosterone, 17β-estradiol, and prostate-specific antigen (PSA). A
meta-analysis ofAKR1C3 mRNA expression in patient samples was also conducted, which  
revealed that AKR1C3 mRNA was upregulated in CRPC, but downregulated in ER-positive  
breast cancer. 11β-PGF2α and testosterone levels in the cell line panel correlated with
 
AKR1C3 protein expression. SN33638 prevented 11 -PGF formation in cell lines that  β 2α
expressed AKR1C3, but partially inhibited testosterone formation and subsequently cell  
proliferation and/or PSA expression only in high (LAPC4 AKR1C3-overexpressing cells) or
 
 
moderate (22RV1) AKR1C3-expressing cell lines. SN33638 had little effect on 17β-estradiol
 
production or estrone-stimulated cell proliferation in ER-positive breast cancer cell lines.
 
Although SN33638 could prevent 11β-PGF2α formation, its ability to prevent testosterone  
and 17β-estradiol production and their roles in CRPC and ER-positive breast cancer progres-  
sion was limited due to AKR1C3-independent steroid hormone production, except in LAPC4  
AKR1C3 cells where the majority of testosterone was AKR1C3-dependent. These results  
suggest that inhibition of AKR1C3 is unlikely to produce therapeutic benefit in CRPC and  
ER-positive breast cancer patients, except possibly in the small subpopulation of CRPC  
patients with tumors that have upregulated AKR1C3 expression and are dependent on  
AKR1C3 to produce the testosterone required for their growth.  
Keywords:AKR1C3, SN33638, castration-resistant prostate cancer, ER-positive breast cancer, 11β-prostaglandin F2α,
testosterone, 17β-estradiol, prostate-specific antigen
INTRODUCTION
Hormone-dependent malignancies, such as breast and prostate
cancer, generally require intracellular concentrations of steroid
hormones for nuclear receptor activation to trigger down-
stream signaling and promote tumor growth (1, 2). However, in
castration-resistant prostate cancer (CRPC) in men and estrogen
receptor (ER)-positive breast cancer in post-menopausal women,
the levels of circulating hormones are diminished. Tumors can
overcome this by producing intracrine hormones from circulating
precursors to activate nuclear receptor signaling (3–5).
The oxidoreductase AKR1C3,also known as 17β-hydroxysteroid
dehydrogenase (17β-HSD) type 5, has been implicated in the
development of CRPC (4, 6–9), and ER-positive breast can-
cer (10, 11), because it can produce androgens locally in these
tissues. AKR1C3 catalyzes the production of potent androgens
testosterone and 5α-dihydrotestosterone in the prostate by reduc-
ing the androgen precursors ∆4-androstene-3,17-dione (12), 5α-
androstane-3,17-dione (13), or androsterone via 3α-diol (14). In
the breast, AKR1C3 can also reduce the weak estrogen estrone to
the potent estrogen 17β-estradiol (10, 12, 14).
AKR1C3 mRNA has been reported to be upregulated in
metastatic and non-metastatic CRPC compared to local prostate
carcinoma (4, 8, 9, 15) and the subsequent de novo synthesis
of androgens in the prostate can drive androgen receptor (AR)
activation and may be responsible for the development of resis-
tance to androgen deprivation therapy in CRPC patients (6, 8,
16). The expression of AKR1C3 in ER-positive breast cancer is
less clear. Although AKR1C3 has been reported to be upregulated
in pre-invasive and malignant breast cancer tissues compared to
normal breast tissue (17, 18), and its expression shown to correlate
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with poor prognosis and an increased rate of late recurrence (18,
19), other studies have found variable or downregulated AKR1C3
expression in breast cancer tissues (20, 21).
AKR1C3 also functions in a steroid-independent manner as
a prostaglandin (PG) F synthase to convert PGH2 to PGF2α and
PGD2 to 9α, 11β-PGF2α (22, 23), an activity that has been shown
to prevent the differentiation of human myeloid leukemia cells
(24, 25). Furthermore, AKR1C3 has been reported to have roles
in xenobiotic metabolism as a carbonyl reductase (26, 27), in the
oxidation of polycyclic aromatic hydrocarbons (28, 29), and in the
aerobic activation of the hypoxia-activated prodrug PR-104 (30,
31).
Due to the numerous enzymatic activities of AKR1C3, its pat-
tern of activity in tissues is determined by its distribution, its cat-
alytic efficiency for the substrate, the availability of the substrate,
and its regulation by steroid hormone levels or the antioxidant
response transcription factor Nrf2 (8, 30, 32, 33). The preferred
action of AKR1C3 in vitro, as determined by its catalytic efficiency,
is its PGD2 11-ketoreductase activity (10, 22, 33). However, in tis-
sues with high enzyme and steroid substrate expression, such as
the breast and prostate (12, 34), 17β-HSD activity may still be
prevalent despite its lower catalytic efficiency relative to PGD2
11-ketoreductase activity (10).
We recently reported the synthesis of a novel series of N -(4-(2-
oxopyrrolidin-1-yl)phenyl)piperidine-1-sulfonamides as potent
and isoform-selective inhibitors of AKR1C3 (35). The lead com-
pound, SN33638, had low nanomolar potency against AKR1C3
and>300-fold selectivity for AKR1C3 over the other AKR1C iso-
forms. This compared favorably with other drugs with AKR1C3
inhibitory activity, such as non-steroidal anti-inflammatory drugs
(NSAIDs; e.g., indomethacin and flufenamic acid), which are less
potent against AKR1C3 and are non-selective for cyclooxygenase
enzymes (36, 37) and medroxyprogesterone acetate (MPA), which
is non-selective for the other AKR1C isoforms (38) (Figure 1).
Here, we investigate AKR1C3 expression and activity across a
panel of CRPC and ER-positive breast cancer cell lines. We use
this cell line panel to evaluate the ability of SN33638 to inhibit
11β-PGF2α, testosterone, and 17β-estradiol production, and to
determine the effect of AKR1C3 inhibition on cell proliferation
and prostate-specific antigen (PSA) expression.
MATERIALS AND METHODS
CHEMICALS
SN33638 was synthesized as described previously (35).
Androstenedione, estrone, indomethacin, flufenamic acid,
medroxyprogesterone acetate, and apigenin, were purchased
from Sigma-Aldrich, 5-(3-bromo-4-hydroxybenzylidene)-3-(4-
methoxyphenyl)-2-thioxothiazolidin-4-1 (17β-HSD3 inhibitor)
was purchased from Merck Millipore and PGD2 was purchased
from Cayman Chemical Company.
CELL CULTURE
The cell lines used are described in Table 1, including their hor-
mone sensitivity and receptor status as previously characterized
(39, 40). All cell lines were sourced from ATCC, except LAPC4
and PC3, which were kindly supplied by Dr. William Aronson and
Dr. Ronnie Cohen, respectively. HCT116, T47D, and LAPC4 cells
FIGURE 1 | Chemical structures of AKR1C3 inhibitors.
were transfected with a plasmid encoding open reading frames
for AKR1C3 that was cloned into an F279-V5puro Gateway®-
compatible vector as described previously (30, 41) using FuGENE®
HD Transfection Reagent (Roche). Cell lines were maintained in
αMEM supplemented with 5% FCS (Moregate Biotech) (HCT116,
NCI-H460), 10% FCS, and 1% PSG (penicillin–streptomycin–
glutamine; Life Technologies) (22RV1, PC3, DU145, LNCaP) or
10% FCS and 0.01–0.02 mg/mL human insulin (Sigma-Aldrich)
(MCF7, T47D), RPMI with 10% FCS (HCC1500), IMDM with
10% FCS and 1% PSG (LAPC4), or DMEM with 10% non-
heat inactivated FCS (VCaP). Transfected cell lines were further
supplemented with 0.5–1.0µM puromycin (Life Technologies).
For drug treatments, cells were seeded in phenol red-free media
(αMEM, RPMI, IMDM, or DMEM as above) supplemented with
5% charcoal-stripped serum (Life Technologies). All media, except
phenol red-free DMEM (Sigma-Aldrich), were purchased from
Life Technologies. LAPC4, LAPC4 AKR1C3, VCaP, and HCC1500
cells were maintained in poly-d-lysine (Becton Dickinson) coated
flasks and 96-well plates.
ONCOMINE ANALYSIS
AKR1C3 and NQO1 gene expression were analyzed using the
publicly accessible online database Oncomine (Compendia Bio-
sciences). mRNA expression was analyzed in all prostate cancer
datasets that contained CRPC samples (Tamura Prostate, Tom-
lins Prostate, Holzbeierlein Prostate, Varambally Prostate, Best
Prostate 2, Chandran Prostate, Grasso Prostate), all breast can-
cer datasets that had normal breast samples, and breast cancer
samples with known hormone status (Curtis Breast, TCGA Breast,
Richardson Breast 2, Gluck Breast, Ma Breast 4, Turashvili Breast,
and Zhao Breast) and in the Barretina cell line dataset. The
AKR1C3 or NQO1 mRNA expression value for each sample was
normalized to the median expressed probeset for that particular
sample.
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Table 1 | Cell line type, hormone-dependence, and receptor status.
Cell Line Tumor type Origin Hormone-dependence Receptor status
HCT116 Colorectal Primary – –
NCI-H460 Large cell lung Pleural effusion – –
LAPC4 Prostate Lymph nodea Androgen sensitive AR-positive
VCaP Prostate Vertebraea Androgen sensitive AR-positive
22RV1 Prostate Primarya Androgen sensitive AR-positive (H874Y mutant)
PC3 Prostate Vertebrae Androgen insensitive AR-negative
DU145 Prostate Brain Androgen insensitive AR-negative
LNCaP Prostate Lymph node Androgen sensitive AR-positive (T877A mutant)
MCF7 Invasive ductal carcinoma (breast) Pleural effusion Estrogen sensitive ER-positive
T47D Invasive ductal carcinoma (breast) Pleural effusion Estrogen sensitive ER-positive
HCC1500 Ductal carcinoma (breast) Primary Estrogen sensitive ER-positive
aCell line established from xenograft.
WESTERN BLOTTING
Cell lysis was carried out for each cell line in modified radioim-
munoprecipitation assay lysis buffer containing 1% protease
inhibitor cocktail (Sigma-Aldrich) on ice for 30 min. Cells were
centrifuged at 13,000 rpm for 5 min at 4°C to remove insoluble
material. Protein concentration of cell lysates was determined by
bicinchoninic acid assay (Sigma-Aldrich) against bovine serum
albumin (BSA; Immuno-Chemical Products Ltd.) standards.
Twenty micrograms of each lysate was loaded onto NuPAGE®
Novex 4–12% Bis–Tris pre-cast 10-well gels (Life Technologies)
and separated by SDS-PAGE at 120 V for 90 min. Each gel was
transferred onto a nitrocellulose membrane (Bio-Rad Laborato-
ries) at 100 V for 70 min and incubated in blocking buffer [PBS
with 0.5% Tween®-20 (Serva) and 5% BSA] for 1 h. Membranes
were washed in PBS with 0.5% Tween®-20 then cut and incu-
bated overnight at 4°C with monoclonal antibodies against either
AKR1C3 (clone NP6.G6.A6; Sigma-Aldrich) at a 1:5000 dilu-
tion in 5% BSA or α-tubulin (clone B-5-1-2; Sigma-Aldrich)
at a dilution of 1:5000 in 5% BSA. Membranes were washed
then incubated with goat anti-mouse IgG HRP-conjugated sec-
ondary antibody (Santa Cruz Biotechnology) at 1:10,000 dilutions
in blocking buffer for 1 h at room temperature. After further
washes, the membranes were incubated with SuperSignal® West
Pico chemiluminescent substrate (Thermo Scientific) for 5 min
prior to imaging on a LAS-3000 luminescent image analyzer
(Fujifilm). Western blots were quantitated using ImageJ 1.45s
software (NIH).
MEASUREMENT OF 11β-PGF2α, TESTOSTERONE, AND 17β-ESTRADIOL
BY ELISA
Cells were seeded into 96-well plates in hormone-deprived media
at appropriate seeding densities [10,000–50,000 cells per well for all
lines except HCC1500 (100,000 cells per well; 11β-PGF2α ELISA)]
to reach approximately 70% confluency at the time of sampling
and were left to settle for 24 h at 37°C and 5% CO2. Inhibitors were
added to the plates at single or multiple concentrations for 1 h
prior to administration of equimolar (28 nM) concentrations of
PGD2 (11β-PGF2α ELISA),androstenedione (testosterone ELISA),
or estrone (17β-estradiol ELISA). The plates were returned to the
incubator for a further 24 h before cell supernatant was removed
for analysis of 11β-PGF2α, testosterone, or 17β-estradiol by ELISA
as per manufacturer’s instructions (11β-PGF2α and testosterone
ELISA, Cayman Chemical Company; 17β-estradiol ELISA, Oxford
Biomedical Research), and cells were fixed for sulforhodamine
B analysis as described below. Each ELISA plate was read at a
wavelength of 405 nM (11β-PGF2α and testosterone) or 650 nM
(17β-estradiol) on a SpectraMax M2 microplate reader (Molecu-
lar Devices) and quantitated against a standard curve generated
in hormone-deprived culture media. Cross-reactivity to PGD2,
androstenedione, or estrone was accounted for by adding these to
cell-free wells of each ELISA plate.
CELL PROLIFERATION
Cells were seeded into 96-well plates in hormone-deprived media
at appropriate seeding densities (5000–20,000 cells per well) to
reach approximately 70% confluency at the time of sampling and
left to settle for 48 h at 37°C and 5% CO2. SN33638 was added to
the plates immediately prior to stimulation with multiple concen-
trations of androstenedione or estrone. The plates were returned
to the incubator for 5 days before fixing in 10% trichloroacetic
acid (Merck Millipore) at 4°C for 1 h and staining with 0.4% sul-
forhodamine B (Sigma-Aldrich) in 1% acetic acid for 30 min in the
dark at room temperature. Plates were washed in 1% acetic acid,
dried, and incubated with unbuffered Tris base (10 mM; Serva)
for 30 min on a plate shaker in the dark to solubilize the stain.
The plates were read on a BioTek EL808 microplate reader at an
absorbance of 490 nM with a reference wavelength of 450 nM.
MEASUREMENT OF PSA CONCENTRATIONS
Cells were seeded at 20,000 cells per well (LAPC4, LAPC4
AKR1C3) or 50,000 cells per well (22RV1) into 96-well plates in
hormone-deprived media and left to settle for 24 h at 37°C and
5% CO2. SN33638 was added to the plates 1 h prior to multiple
concentrations of androstenedione. The plates were returned to
the incubator for 24 h, before the cell supernatant was removed
and frozen for PSA analysis. Determination of total PSA con-
centration was carried out at LabPLUS, Auckland City Hospi-
tal, by immunoassay on a Cobas® e601 analyzer according to
manufacturer’s instructions (Roche).
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RESULTS
AKR1C3 MRNA IS UPREGULATED IN CRPC PATIENTS BUT
DOWNREGULATED IN BREAST CANCER PATIENTS
We analyzed the online microarray database Oncomine to deter-
mine the AKR1C3 mRNA expression levels in CRPC and breast
cancer patients relative to normal tissue or primary disease. Meta-
analysis of seven prostate cancer datasets that included normal
prostate or primary prostate carcinoma samples in addition to
CRPC revealed that AKR1C3 expression is significantly upreg-
ulated in CRPC relative to both normal prostate and primary
prostate carcinoma (P < 0.001; one-way ANOVA with Dunnett’s
multiple comparison analysis; Figure 2A). The magnitude of this
difference was most evident in the highest AKR1C3-expressing
samples, where the upper quartile of CRPC corresponded to the
97th percentile of primary prostate carcinoma and above the 100th
percentile for normal prostate. Since AKR1C3 is regulated by Nrf2
(32), we also analyzed the samples for mRNA expression of NQO1,
a reporter of Nrf2 activity (42, 43), to determine if the upregula-
tion of AKR1C3 in CRPC samples was driven by increased Nrf2
activity. NQO1 mRNA levels were unchanged in CRPC relative to
normal prostate or primary prostate carcinoma (data not shown)
and there was no significant correlation between NQO1 mRNA
and AKR1C3 mRNA expression in CRPC patients (R2= 0.02;
Pearson product-moment correlation; Figure 2B). A similar meta-
analysis was conducted across seven breast cancer datasets that
included normal breast samples, showing that AKR1C3 mRNA
expression is significantly downregulated in breast cancer samples
relative to normal breast tissue (P < 0.001; one-way ANOVA with
Dunnett’s multiple comparison analysis; Figure 2C), including in
paired samples from post-menopausal ER-positive breast cancer
patients (P < 0.0001) (Figure 2D).
AKR1C3 PROTEIN EXPRESSION IS VARIABLE IN PROSTATE AND
BREAST CANCER CELL LINES
We generated a cell line panel of prostate and ER-positive breast
cancer cell lines and evaluated AKR1C3 protein expression by
western blotting in comparison to cell lines with high (NCI-H460
NSCLC and HCT116 AKR1C3-overexpressing colon cancer cells)
FIGURE 2 |AKR1C3 mRNA expression is upregulated in tumor
samples from CRPC patients but downregulated in breast cancer
patient tumors. (A) Meta-analysis of AKR1C3 mRNA expression in
normal prostate (n=54), primary prostate carcinoma (n=133), and
CRPC (n=100) tissue in patients from seven Oncomine prostate cancer
datasets. The upper dotted line indicates 75th percentile for CRPC.
(B) Correlation of NQO1 mRNA expression with AKR1C3 mRNA
expression in CRPC patients from (A). (C) Meta-analysis of AKR1C3
mRNA expression in normal breast (Normal, n=257), premenopausal
ER-positive breast cancer (ER+ pre, n=281), post-menopausal
ER-positive breast cancer (ER+ post, n=1337), premenopausal
ER-negative breast cancer (ER− pre, n=189), and post-menopausal
ER-negative breast cancer (ER− post, n=278) patients in seven
Oncomine breast cancer datasets. The line in each box represents the
median, the lower, and upper boundaries represent the 25th and 75th
percentiles, and the whiskers show the 5th and 95th percentiles.
(D) AKR1C3 mRNA expression in paired normal and ER-positive breast
cancer samples in post-menopausal women (n=23) from (C).
Significance of differences was evaluated by one-way ANOVA with
Dunnett’s multiple comparison analysis (A,C) or by Student’s t -test (D).
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and low (HCT116 wild-type) AKR1C3 expression. To ensure the
panel included CRPC and ER-positive breast cancer cell lines with
high AKR1C3 expression, we transfected LAPC4 and T47D cells
with an AKR1C3 plasmid to generate AKR1C3-overexpressing cell
lines. The stably transfected cell lines had high protein expression
of AKR1C3, similar to NCI-H460 and HCT116 AKR1C3, in con-
trast to the wild-type lines (LAPC4 and T47D), which had very
low AKR1C3 expression (Figure 3A). Moderate protein expres-
sion was observed in 22RV1, VCaP, PC3, and DU145 prostate
cancer cells and in MCF7 breast cancer cells. Overall, the protein
expression in the cell line panel correlated well with the mRNA
expression data for these cell lines reported in the Barretina cell line
dataset in Oncomine (R= 0.778; P < 0.01; Spearman’s rank-order
correlation).
SN33638 PREVENTS THE PGD2 11-KETOREDUCTASE ACTIVITY OF
AKR1C3
The PGD2 11-ketoreductase activity of AKR1C3 was determined
by stimulating the cell line panel with PGD2 for 24 h, then detect-
ing 11β-PGF2α levels by ELISA. The formation of 11β-PGF2α in
the cell line panel correlated well with AKR1C3 protein expres-
sion (R= 0.907, P < 0.0001; Spearman’s rank-order correlation;
Figure 3B). Addition of the AKR1C3 inhibitor SN33638 at 10µM
dramatically reduced 11β-PGF2α levels by ≥80% in all cell lines
that expressed AKR1C3 (Figure 3C). Varying concentrations of
SN33638, MPA, indomethacin, and flufenamic acid were added
to HCT116 AKR1C3 cells to determine the potency of these
drugs at inhibiting the formation of 11β-PGF2α from PGD2.
SN33638 completely inhibited 11β-PGF2α formation at an EC50
of 20.5± 5.3 nM (Figure 3D), while MPA was approximately 100-
fold less potent (EC50= 2.4± 1.6µM) and indomethacin and
flufenamic acid were inactive at all concentrations tested up to
30µM. Addition of PGD2 or SN33638 to cells for 24 h had no
effect on cell proliferation relative to unstimulated controls in all
cell lines (data not shown).
SN33638 INHIBITS TESTOSTERONE PRODUCTION IN HIGH
AKR1C3-EXPRESSING CELL LINES
Since AKR1C3 has been implicated in the development of CRPC
because of its ability to produce testosterone intratumorally from
circulating androstenedione, we determined testosterone concen-
trations in the prostate cancer cell lines and known high and low
AKR1C3-expressing cells after stimulation with androstenedione
for 24 h. Similarly to 11β-PGF2α, testosterone levels positively cor-
related with AKR1C3 protein expression (R= 0.792, P < 0.01;
Spearman’s rank-order correlation; Figure 4A). However, other
than in LAPC4 AKR1C3-overexpressing cells, testosterone levels
in the prostate cancer cell lines were no higher than in the negative
control HCT116 (Figure 4B). Addition of 10µM SN33638 signif-
icantly reduced testosterone levels in the high AKR1C3-expressing
HCT116 AKR1C3 (74.2% inhibition, P < 0.001; Student’s t -test),
LAPC4 AKR1C3 (96.8% inhibition, P < 0.05), and NCI-H460
FIGURE 3 | PGD2 11-ketoreductase activity correlates with AKR1C3
protein expression and can be inhibited by SN33638. (A) AKR1C3
and α-tubulin protein expression by western blotting in the cell line panel.
(B) Correlation between 11β-PGF2α formation following stimulation with
28 nM PGD2 (n= 2–6) and AKR1C3 protein expression (average of two to
three independent lysates) in the cell line panel. (C) 11β-PGF2α formation
in the cell line panel after stimulation with PGD2 in the presence or
absence of 10µM SN33638 (n=2–6). (D) EC50 plot of inhibition of
11β-PGF2α production by SN33638 following stimulation with PGD2 in
HCT116 AKR1C3 cells (n=2–3). Bars or symbols represent the
mean±SEM. Statistical significance of correlation analysis was
evaluated by Spearman’s rank-order correlation and of differences
between mean values by Student’s t -test. *P <0.05; **P <0.01;
***P <0.001 vs. no inhibitor controls.
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FIGURE 4 |Testosterone production correlates with AKR1C3 protein
expression and can be partially inhibited by SN33638 in high
AKR1C3-expressing cell lines. Testosterone levels were determined by
ELISA 24 h after stimulation with 28 nM androstenedione. (A) Correlation
between testosterone levels (n=3–6) and AKR1C3 protein expression
(average of 2–3 independent lysates) in the prostate cancer, HCT116, and
NCI-H460 cell lines. (B) Concentration of testosterone in the cell lines in the
presence or absence of 10µM SN33638 (n=3–6). (C) EC50 plot of the
inhibition of testosterone production by SN33638 in HCT116 AKR1C3 cells
(n=3). (D) Testosterone levels in HCT116 AKR1C3, NCI-H460, 22RV1, and
LAPC4 cell lines following treatment with 10µM SN33638 and 1µM
17β-HSD3 inhibitor alone or in combination (n=3–6). Bars or symbols
represent the mean±SEM. Statistical significance of correlation analysis was
evaluated by Spearman’s rank-order correlation and of differences between
mean values by Student’s t -test (B) or two-way ANOVA with Tukey’s multiple
comparison analysis (D).*P <0.05; **P <0.01; ***P <0.001 vs. no inhibitor
controls. Statistically significant differences between treatment groups are
marked as indicated.
cell lines (54.1% inhibition, P < 0.05), but only in one moderate
AKR1C3-expressing cell line: 22RV1 (50.8% inhibition,P < 0.05).
In LNCaP cells, testosterone levels were lower than the negative
control after androstenedione stimulation alone, but were signif-
icantly increased on addition of 10µM SN33638 to levels similar
to those seen in the negative control and other prostate cancer cell
lines (P < 0.05).
SN33638 potently inhibited testosterone production in HCT116
AKR1C3 cells with an EC50 of 7.4± 1.2 nM (Figure 4C) compared
to MPA (EC50= 4.3± 2.6µM), indomethacin (EC50> 30µM),
and flufenamic acid (EC50> 30µM); however, only approxi-
mately 70% of the testosterone produced in these cells could
be inhibited by the AKR1C3 inhibitors. When testosterone for-
mation was limited to that which was inhibitable by SN33638,
the correlation with AKR1C3 protein expression (R= 0.951,
P < 0.0001; Spearman’s rank-order correlation) was significantly
improved (z = 2.561, P < 0.05; Steiger’s z-test) relative to the
correlation between total testosterone and AKR1C3 protein
expression. Since 17β-HSD3 can also convert androstenedione to
testosterone, cells were treated with a non-cytotoxic dose (1µM)
of a 17β-HSD3 inhibitor (5-(3-bromo-4-hydroxybenzylidene)-3-
(4-methoxyphenyl)-2-thioxothiazolidin-4-1) alone and in com-
bination with SN33638. The 17β-HSD3 inhibitor significantly
reduced testosterone levels in HCT116 AKR1C3 cells by 32.1% as
a single agent (P < 0.01; two-way ANOVA with Tukey’s multiple
comparison analysis) and by 97.3% in combination with SN33638
(P < 0.0001), an effect significantly greater than that achieved by
SN33638 (73.7% inhibition, P < 0.05 vs. combination) or 17β-
HSD3 inhibitor (P < 0.0001 vs. combination) treatment alone
(Figure 4D). Inhibition of 17β-HSD3 had no effect on testos-
terone production either alone or in combination with SN33638
in the other cell lines tested (NCI-H460, 22RV1, and LAPC4).
SN33638 DOES NOT SUBSTANTIALLY INHIBIT 17β-ESTRADIOL
PRODUCTION IN ER-POSITIVE BREAST CANCER CELL LINES
17β-estradiol is predominantly produced from estrone by 17β-
HSD1 in breast tissue in post-menopausal women (44). Although
less catalytically efficient than 17β-HSD1, AKR1C3 can also
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convert estrone to 17β-estradiol (10, 12, 14), and therefore, may
play a role in ER-positive breast cancer development. To investigate
the activity of AKR1C3 in 17β-estradiol production, ER-positive
breast cancer cells and known high and low AKR1C3-expressing
cells were stimulated with estrone for 24 h prior to determina-
tion of 17β-estradiol levels by ELISA. Unlike 11β-PGF2α and
testosterone, 17β-estradiol levels did not significantly correlate
with AKR1C3 protein expression in the cell lines investigated
(R= 0.429; Spearman’s rank-order correlation; Figure 5A), indi-
cating that AKR1C3 is not responsible for estrone reduction in
some/all of these cell lines. 17β-estradiol levels were highest in
T47D and T47D AKR1C3 cell lines, despite the large difference
in AKR1C3 expression in this isogenic cell line pair. Addition of
10µM SN33638 had no effect on the high 17β-estradiol levels in
T47D and T47D AKR1C3 cells, but did inhibit 17β-estradiol for-
mation by 16.0% in MCF7 cells (P < 0.05; Student’s t -test) and
by 39.6% in NCI-H460 cells (P < 0.05) (Figure 5B). To determine
if 17β-HSD1 was predominantly responsible for estrone reduc-
tion, the ER-positive breast cancer cell lines were also treated with
apigenin, an inhibitor of 17β-HSD1 activity (45). Apigenin signif-
icantly inhibited 17β-estradiol formation in both T47D and T47D
AKR1C3 cells (P < 0.05; one-way ANOVA with Dunnett’s multi-
ple comparison analysis; Figure 5C), but had no inhibitory activity
on MCF7 or HCC1500 cells (data not shown).
SN33638 SUPPRESSES PSA LEVELS IN AKR1C3-EXPRESSING CRPC
CELLS
Next, PSA expression was determined in the CRPC cell lines
that were sensitive to SN33638-mediated inhibition of testos-
terone (LAPC4 AKR1C3 and 22RV1 with LAPC4 wild-type cells
acting as a negative control) as a biomarker of AR activity.
Cells were stimulated with physiological concentrations of up
to 10 nM androstenedione, with or without SN33638, for 24 h
before PSA concentrations were determined. Androstenedione
stimulation promoted PSA production in all three cell lines,
with the highest PSA levels observed in LAPC4 AKR1C3 cells.
SN33638 treatment significantly inhibited the formation of PSA
in LAPC4 AKR1C3 cells that was attributable to stimulation with
1 nM (90.8% inhibition, P < 0.001; Student’s t -test) and 10 nM
androstenedione (57.4% inhibition, P < 0.05), and in 22RV1 cells
with 10 nM androstenedione (44.9% inhibition,P < 0.05),but had
no significant effect on LAPC4 wild-type cells (Figure 6A).
SN33638 HAS LIMITED INHIBITORY ACTIVITY ON ANDROSTENEDIONE
OR ESTRONE-STIMULATED CELL PROLIFERATION
Finally, we investigated whether inhibiting AKR1C3-dependent
testosterone or 17β-estradiol production could prevent
androstenedione- or estrone-stimulated cell proliferation in CRPC
or ER-positive breast cancer cells. The AKR1C3-overexpressing
and wild-type cell line pairs, 22RV1 and MCF7 cells were stim-
ulated with physiological concentrations of androstenedione or
estrone, with or without 10µM SN33638, for 5 days. To limit the
effect on cell proliferation of the testosterone or 17β-estradiol that
could not be inhibited by SN33638 and due to the longer duration
of the assay, lower concentrations of androstenedione, and estrone
(up to 10 nM) were used than in the ELISA assays. SN33638 had no
effect on unstimulated cell proliferation in all cell lines, except for a
FIGURE 5 | SN33638 has little effect on estrone reduction to
17β-estradiol in ER-positive breast cancer cell lines. 17β-estradiol levels
were determined by ELISA 24 h after stimulation with 28 nM estrone.
(A) Correlation between 17β-estradiol levels (n=3–4) and AKR1C3 protein
expression (average of 2–3 independent lysates) in ER-positive breast
cancer, HCT116, and NCI-H460 cell lines. (B) Concentration of 17β-estradiol
in the cell lines in the presence and absence of 10µM SN33638 (n=3–4).
(C) 17β-estradiol levels in T47D and T47D AKR1C3 cells following treatment
with 10µM SN33638 and 30µM apigenin alone or in combination (n=3).
Bars or symbols represent the mean±SEM. Statistical significance of
correlation analysis was evaluated by Spearman’s rank-order correlation and
of differences between mean values by Student’s t -test (B) or one-way
ANOVA with Dunnett’s multiple comparison analysis (C). *P <0.05;
**P <0.01 vs. no inhibitor controls.
7.3% reduction in MCF7 cells (P < 0.05; Student’s t -test), indicat-
ing it was largely non-cytotoxic at 10µM. Stimulation of prolifer-
ation was observed with all concentrations of androstenedione in
high AKR1C3-expressing LAPC4 AKR1C3 cells, but only at 1 and
10 nM in LAPC4 wild-type and 22RV1 cells. SN33638 significantly
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FIGURE 6 | SN33638 partially inhibits PSA expression and cell
proliferation in LAPC4 AKR1C3 cells, but has limited activity on
low-moderate AKR1C3-expressing CRPC cells and ER-positive breast
cancer cells. (A) PSA levels in CRPC cell lines 24 h after stimulation with
androstenedione in the presence or absence of 10µM SN33638 (n=3). Cell
proliferation in (B) CRPC cell lines and (C) breast cancer cell lines 5 days after
stimulation with androstenedione or estrone and treatment with or without
10µM SN33638 (n=3–4). Bars represent the mean±SEM. Significance of
differences was evaluated by Student’s t -test. *P <0.05; ***P < 0.001 vs. no
inhibitor controls.
inhibited androstenedione-stimulated cell proliferation at 0.1 nM
(101.4% inhibition, P < 0.05; Student’s t -test) and caused a sub-
stantial (45.9%) but non-significant reduction in stimulated cell
proliferation with 1 nM androstenedione in LAPC4 AKR1C3 cells,
but had no effect on androstenedione-stimulated cell proliferation
in LAPC4 wild-type cells and 22RV1 cells (Figure 6B). Consis-
tent with the lack of effect on 22RV1 cell proliferation, SN33638
had no inhibitory effect on 22RV1 testosterone levels 5 days after
stimulation with up to 10 nM androstenedione (data not shown).
Estrone effectively stimulated cell proliferation in MCF7, T47D,
and T47D AKR1C3 ER-positive breast cancer cells; however,
this stimulation was not significantly inhibited by SN33638,
other than a minor reduction in MCF7 cells at 10 nM estrone
(14.9% inhibition, P < 0.05; Student’s t -test) (Figure 6C). Nei-
ther androstenedione nor estrone-stimulated cell proliferation in
the HCT116 AKR1C3 and wild-type cell lines (data not shown).
DISCUSSION
AKR1C3 has recently been identified as a potential thera-
peutic target in both CRPC and ER-positive breast cancer,
since it can promote intratumoral steroidogenesis to provide
the hormones required for nuclear receptor activation and
tumor progression (4, 6, 8–11). Several AKR1C3 inhibitors are
currently being investigated [reviewed in Ref. (46)], includ-
ing the oxopyrrolidinylphenylpiperidinosulfonamide compound
SN33638 (Figure 1) (35). Here, we characterized the in vitro
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biological activity of SN33638 using a panel of CRPC and
ER-positive breast cancer cell lines to determine if inhibition
of AKR1C3 could prevent steroid hormone production, PSA
expression, and cell proliferation.
We conducted a meta-analysis of AKR1C3 mRNA expression
data from multiple patient datasets that revealed that AKR1C3
is upregulated in CRPC but downregulated in ER-positive breast
cancer relative to normal prostate or breast tissues. The CRPC data
confirmed previous reports (4, 8, 9, 47, 48), but our larger dataset
showed AKR1C3 upregulation was restricted to the upper quartile
of CRPC samples. The lack of correlation between AKR1C3 and
NQO1 expression in CRPC patient samples suggests that AKR1C3
upregulation is not driven by an NRF2-mediated response to
oxidative or electrophilic stress (32), but likely by a feedback loop
in which low levels of androgens in patients undergoing androgen
deprivation therapy upregulate AKR1C3 to mediate intratumoral
androgen levels (8, 48, 49). Previous studies on AKR1C3 mRNA
expression in small groups of invasive ductal carcinoma patients
have generated conflicting data on whether AKR1C3 is up- or
downregulated relative to normal breast tissue (17, 20, 21). How-
ever, our meta-analysis of a much larger cohort of patients showed
AKR1C3 is downregulated in ER-positive breast cancer, suggesting
that AKR1C3 is unlikely to be a suitable therapeutic target for this
disease.
Reduction of PGD2 to 11β-PGF2α correlated linearly with
AKR1C3 protein expression in the cancer cell line panel, indi-
cating that PGD2 reduction provides a measurable biomarker of
AKR1C3 activity in cells. This was confirmed by the presence of
minimal 11β-PGF2α concentrations in all cell lines treated with
SN33638. A large concentration of SN33638 (10µM) was used
throughout these studies to ensure near-complete inhibition of
AKR1C3 activity was achieved (Figure 3D), while maintaining
cell viability and selectivity over other AKR1C isoforms (<14%
inhibition against each isolated enzyme at 10µM, unpublished
data). AKR1C3 activity was variable across the cell line panel, with
genetic overexpression required to produce activity similar to or
greater than that observed in the known high AKR1C3-expressing
NCI-H460 NSCLC cell line. Although VCaP cells have been used
elsewhere to investigate the activity of small molecule inhibitors
of AKR1C3 or RNAi in CRPC (6, 50), they displayed low AKR1C3
expression and activity in our studies. We therefore engineered
an AKR1C3-overexpressing LAPC4 cell line to model the CRPC
patients that had high AKR1C3 mRNA expression.
Similarly to 11β-PGF2α formation, the production of testos-
terone from androstenedione also correlated linearly with
AKR1C3 protein expression, with AKR1C3 overexpression sub-
stantially increasing testosterone production, confirming that
AKR1C3 plays an important role in this process. However,
unlike 11β-PGF2α, testosterone was present in every cell line,
including those that do not express AKR1C3, even after treat-
ment with SN33638 or MPA. By limiting testosterone produc-
tion to that which was SN33638-inhibitable, the correlation with
AKR1C3 expression was significantly improved, suggesting that
AKR1C3 was not the sole enzyme responsible for testosterone
production, but that it does generate the majority of testos-
terone in high AKR1C3-expressing cell lines, especially LAPC4
AKR1C3, where 96.8% of testosterone was AKR1C3-dependent.
AKR1C3-independent testosterone levels could be partially attrib-
uted to redundancy in androstenedione reduction by 17β-HSD3
(51) as evidenced in HCT116 AKR1C3 cells, where single agent
treatment with a 17β-HSD3 inhibitor partially prevented testos-
terone formation, while combination treatment with a 17β-HSD3
inhibitor and SN33638 almost completely inhibited testosterone
production. However, 17β-HSD3 inhibition had no effect on
testosterone production, with or without SN33638, in NCI-H460,
22RV1, and LAPC4 cells, suggesting the involvement of one or
more other 17β-HSD isoforms in testosterone production in these
cells. These may include 17β-HSD types 1 and 15, which have both
been shown to have a low capacity to convert androstenedione to
testosterone (52, 53). Interestingly, testosterone levels in LNCaP
cells were unexpectedly increased by SN33638 to similar levels to
those detected in AKR1C3-negative cell lines. It is unclear why
AKR1C3 inhibition promoted testosterone production in LNCaP
cells, although it may be due to feedback upregulation of other
17β-HSD enzymes, which were likely to be present in LNCaP cells
at lower levels than other CRPC cell lines given the low basal
testosterone levels observed.
SN33638-mediated inhibition of testosterone production led
to partial suppression of AR signaling as evidenced by reduc-
tions in PSA expression in LAPC4 AKR1C3 and 22RV1 cells and
proliferation in LAPC4 AKR1C3 cells. Higher androstenedione
concentrations were required to stimulate PSA (24 h incubation)
than cell proliferation (5-day incubation) as more testosterone
was produced with longer incubation times of androstenedione
(data not shown). AKR1C3-independent testosterone concentra-
tions also increased with longer incubation times and/or increased
androstenedione concentrations, and are likely to account for
the lack of effect of SN33638 on testosterone production or
proliferation over the 5-day incubation in 22RV1 cells and
on LAPC4 AKR1C3 cell proliferation with higher androstene-
dione concentrations. AKR1C3-independent testosterone produc-
tion may also explain the observed stimulation of proliferation
and PSA expression in the low AKR1C3-expressing LAPC4 cell
line. These results suggest that AKR1C3 inhibition may prevent
androstenedione-stimulated PSA expression or cell proliferation
in CRPC cells, as previously shown for other small molecule
inhibitors of AKR1C3 or RNAi (6, 47, 50), but because of the
role of AKR1C3-independent testosterone (and DHT) in AR acti-
vation, the inhibitory effect is likely to be limited to CRPC cells
that express high levels of AKR1C3 and to conditions where the
cells are dependent on AKR1C3 for the generation of testosterone.
The greatest inhibitory effects of SN33638 were observed in
the LAPC4 AKR1C3 cell line, which is an artificial experimental
model. Whether similar effects of SN33638 would be observed in
high AKR1C3-expressing wild-type cell lines is unknown, because
of the dearth of CRPC cell lines available that express high levels of
AKR1C3. This is surprising given the evidence here and elsewhere
that AKR1C3 is upregulated in a subset of CRPC tumors (4, 8, 9,
47, 48). To address this issue, future studies of AKR1C3 inhibitors
would benefit from utilizing CRPC patient-derived xenografts (54)
from tumors that express high levels of AKR1C3. Such models
could identify whether AKR1C3 inhibitors prevent the growth of
tumors that originated from those patients that would be the most
obvious candidates for treatment with this class of agents, but they
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would provide limited toxicology information since there is no
AKR1C3 homolog in mice (55).
AKR1C3 has also been implicated in the development of ER-
positive breast cancer because of its ability to convert estrone to
17β-estradiol (10, 11). However, we observed a poor correlation
between AKR1C3 protein expression and estrone reduction to
17β-estradiol, while SN33638 was largely ineffective at prevent-
ing estrone reduction or estrone-stimulated cell proliferation in
ER-positive breast cancer cell lines. T47D cells produced high
levels of 17β-estradiol that could not be reduced by SN33638
treatment nor increased by AKR1C3 overexpression, but could
be partially inhibited by apigenin or, as described previously, by
the potent 17β-HSD1 inhibitor PBRM (56). This suggests a role
for 17β-HSD1 in 17β-estradiol production in this cell line, with
17β-HSD7 and to a lesser extent 17β-HSD12 also likely to con-
tribute since high levels of these enzymes are present in T47D
cells (44, 57). The only breast cancer cell line in which SN33638
showed some inhibitory activity was MCF7, where we observed a
16% reduction in estradiol formation, similar to that previously
reported for a steroidal lactone AKR1C3 inhibitor in this cell line
(57). Despite MCF7 cells having low AKR1C3 protein expression,
they appear to be partially dependent on AKR1C3 to produce 17β-
estradiol, since the mRNA expression of AKR1C3 in this cell line
has been reported to be greater than that of the other 17β-HSD
isoforms (types 1, 7, 12) that are capable of converting estrone
to 17β-estradiol (57). Minor inhibition of estrone-stimulated cell
proliferation was observed with SN33638 in MCF7 cells, but since
inhibition was also observed in the absence of estrone stimulation,
this effect may have been independent of the inhibition of estrone
reduction. Overall, these results suggest that inhibition of AKR1C3
by SN33638 is ineffective at preventing ER-positive breast cancer
growth.
In conclusion, our data suggests that while inhibition of
AKR1C3 by SN33638 can prevent the conversion of PGD2 to
11β-PGF2α, its activity at preventing steroid hormone reduction
and resultant CRPC and ER-positive breast cancer growth is lim-
ited due to the involvement of additional enzymes in testosterone
and 17β-estradiol synthesis. AKR1C3 inhibitor therapy is therefore
unlikely to be beneficial for the treatment of CRPC and ER-positive
breast cancer, except possibly in the small subpopulation of CRPC
patients with tumors that have upregulated AKR1C3 expression
and are dependent on AKR1C3 for producing the testosterone
required for their growth.
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